[go: up one dir, main page]

WO1998010767A3 - Utilisation de derives de la quinazoline pour la fabrication d'un medicament destine au traitement de troubles cutanes hyperproliferatifs - Google Patents

Utilisation de derives de la quinazoline pour la fabrication d'un medicament destine au traitement de troubles cutanes hyperproliferatifs Download PDF

Info

Publication number
WO1998010767A3
WO1998010767A3 PCT/US1997/016145 US9716145W WO9810767A3 WO 1998010767 A3 WO1998010767 A3 WO 1998010767A3 US 9716145 W US9716145 W US 9716145W WO 9810767 A3 WO9810767 A3 WO 9810767A3
Authority
WO
WIPO (PCT)
Prior art keywords
medicament
skin disorders
manufacture
treatment
hyperproliferative skin
Prior art date
Application number
PCT/US1997/016145
Other languages
English (en)
Other versions
WO1998010767A2 (fr
WO1998010767A9 (fr
Inventor
Gerald Mcmahon
Laura Kay Shawver
Blair Narog
Peng Cho Tang
Klaus Peter Hirth
Original Assignee
Sugen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sugen Inc filed Critical Sugen Inc
Priority to EP97941542A priority Critical patent/EP0954315A2/fr
Priority to AU43429/97A priority patent/AU4342997A/en
Priority to CA002265630A priority patent/CA2265630A1/fr
Publication of WO1998010767A2 publication Critical patent/WO1998010767A2/fr
Publication of WO1998010767A9 publication Critical patent/WO1998010767A9/fr
Publication of WO1998010767A3 publication Critical patent/WO1998010767A3/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention se rapporte à des procédés et à des compositions permettant de traiter des troubles cutanés hyperprolifératifs, qui font usage d'un dérivé de la quinazoline en tant qu'ingrédient actif.
PCT/US1997/016145 1996-09-13 1997-09-11 Utilisation de derives de la quinazoline pour la fabrication d'un medicament destine au traitement de troubles cutanes hyperproliferatifs WO1998010767A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP97941542A EP0954315A2 (fr) 1996-09-13 1997-09-11 Utilisation de derives de la quinazoline pour la fabrication d'un medicament destine au traitement de troubles cutanes hyperproliferatifs
AU43429/97A AU4342997A (en) 1996-09-13 1997-09-11 Use of quinazoline derivatives for the manufacture of a medicament in the reatment of hyperproliferative skin disorders
CA002265630A CA2265630A1 (fr) 1996-09-13 1997-09-11 Utilisation de derives de la quinazoline pour la fabrication d'un medicament destine au traitement de troubles cutanes hyperproliferatifs

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US2606796P 1996-09-13 1996-09-13
US60/026,067 1996-09-13
US3143696P 1996-11-20 1996-11-20
US60/031,436 1996-11-20
US3498197P 1997-01-08 1997-01-08
US60/034,981 1997-01-08
US4837297P 1997-06-03 1997-06-03
US60/048,372 1997-06-03

Publications (3)

Publication Number Publication Date
WO1998010767A2 WO1998010767A2 (fr) 1998-03-19
WO1998010767A9 WO1998010767A9 (fr) 1998-07-02
WO1998010767A3 true WO1998010767A3 (fr) 1998-08-06

Family

ID=27487474

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/016145 WO1998010767A2 (fr) 1996-09-13 1997-09-11 Utilisation de derives de la quinazoline pour la fabrication d'un medicament destine au traitement de troubles cutanes hyperproliferatifs

Country Status (4)

Country Link
EP (1) EP0954315A2 (fr)
AU (1) AU4342997A (fr)
CA (1) CA2265630A1 (fr)
WO (1) WO1998010767A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7160889B2 (en) 2000-04-07 2007-01-09 Astrazeneca Ab Quinazoline compounds
US7173038B1 (en) 1999-11-05 2007-02-06 Astrazeneca Ab Quinazoline derivatives as VEGF inhibitors
USRE42353E1 (en) 1996-09-25 2011-05-10 Astrazeneca Uk Limited Quinazoline derivatives and pharmaceutical compositions containing them

Families Citing this family (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL125686A (en) 1996-02-13 2002-11-10 Zeneca Ltd Quinazoline derivatives, processes for their preparation, pharmaceutical preparations containing them and their use in the manufacture of a drug with an anti-angiogenic effect and / or an effect of reducing vascular permeability
IL125954A (en) 1996-03-05 2003-06-24 Zeneca Ltd Quinazoline derivatives, processes for their preparation, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments having an antiangiogenic and/or vascular permeability reducing effect
US6258820B1 (en) 1999-03-19 2001-07-10 Parker Hughes Institute Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines
US6126917A (en) * 1999-06-01 2000-10-03 Hadasit Medical Research Services And Development Ltd. Epidermal growth factor receptor binding compounds for positron emission tomography
AU2001272028A1 (en) * 2000-06-26 2002-01-08 The Regents Of The University Of Michigan Use of egf-r protein tyrosine kinase inhibitors for preventing photoaging in human skin
DE60144284D1 (de) 2000-11-01 2011-05-05 Millennium Pharm Inc Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung
PT3345602T (pt) 2001-02-19 2022-07-04 Novartis Pharma Ag Derivado de rapamicina para tratamento de tumores sólidos
AU2002342335B2 (en) 2001-05-16 2006-02-02 Novartis Ag Combination comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
EP1505959B1 (fr) 2002-05-16 2008-10-29 Novartis AG Utilisation d'agents de liaison du recepteur edg dans le cancer
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
JP4944613B2 (ja) 2003-05-19 2012-06-06 アイアールエム・リミテッド・ライアビリティ・カンパニー 免疫抑制化合物および組成物
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
CN1964970B (zh) 2004-04-07 2011-08-03 诺瓦提斯公司 Iap的抑制剂
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
KR20070117547A (ko) * 2005-01-03 2007-12-12 미리어드 제네틱스, 인크. 뇌암 치료방법
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0519879D0 (en) 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process
PT2275103E (pt) 2005-11-21 2014-07-24 Novartis Ag Inibidores de mtor para o tratamento de tumores endócrinos
CA2637573C (fr) 2006-02-21 2013-07-02 Eisai R&D Management Co., Ltd. Derives de 4-(3-benzoylaminophenyl)-6,7-dimethoxy-2-methylaminoquinazoline
GB0605120D0 (en) 2006-03-14 2006-04-26 Novartis Ag Organic Compounds
WO2007115289A2 (fr) 2006-04-05 2007-10-11 Novartis Ag Combinaisons d'agents thérapeutiques destinées à traiter le cancer
CN101415409B (zh) 2006-04-05 2012-12-05 诺瓦提斯公司 用于治疗癌症的治疗剂的组合
BRPI0711385A2 (pt) 2006-05-09 2011-11-08 Novartis Ag combinação compreendendo um quelante de ferro e um agente anti-neoplástico e seu uso
JP2010504933A (ja) 2006-09-29 2010-02-18 ノバルティス アーゲー Pi3k脂質キナーゼ阻害剤としてのピラゾロピリミジン
MX2009008584A (es) 2007-02-15 2009-08-18 Novartis Ag Combinacion de lbh589 con otros agentes terapeuticos para el tratamiento de cancer.
EP2123641A4 (fr) 2007-02-16 2011-06-22 Eisai R&D Man Co Ltd Cristal, forme amorphe et sel d'acide téréphtalique de méthyle n-ý3-(6,7-diméthoxy- 2-méthylaminoquinazoline-4-yl)phényle¨
CN102532041A (zh) 2007-08-17 2012-07-04 卫材R&D管理有限公司 喹唑啉衍生物的制造方法
AU2008290001B2 (en) 2007-08-17 2012-08-09 Eisai R & D Management Co., Ltd. Novel preparation for external use
CN102036953B (zh) 2008-03-24 2015-05-06 诺华股份有限公司 基于芳基磺酰胺的基质金属蛋白酶抑制剂
BRPI0909159A2 (pt) 2008-03-26 2015-11-24 Novartis Ag inibidores baseados em hidroxamato de desacetilases b
ES2704986T3 (es) 2008-10-16 2019-03-21 Celator Pharmaceuticals Inc Combinaciones de una camptotecina liposomal soluble en agua con cetuximab o bevacizumab
CN102256942B (zh) 2008-12-18 2013-07-24 诺瓦提斯公司 1-(4-{1-[(e)-4-环己基-3-三氟甲基-苄氧基亚氨基]-乙基}-2-乙基-苄基)-氮杂环丁烷-3-甲酸的多晶型物
PL2676953T3 (pl) 2008-12-18 2017-09-29 Novartis Ag Sól hemifumaranowa kwasu 1-[4-[1-(4-cykloheksylo-3-trifluorometylobenzyloksyimino)-etylo]-2-etylobenzylo]-azetydyno-3-karboksylowego
MX2011006622A (es) 2008-12-18 2011-07-12 Novartis Ag Sales novedosas.
WO2010083617A1 (fr) 2009-01-21 2010-07-29 Oncalis Ag Pyrazolopyrimidines en tant qu'inhibiteurs de protéines kinases
PT2391366E (pt) 2009-01-29 2013-02-05 Novartis Ag Benzimidazoles substituídos para o tratamento de astrocitomas
PT2445903E (pt) 2009-06-26 2014-07-08 Novartis Ag Derivados de imidazolidin-2-ona 1,3-dissubstituídos como inibidores de cyp17
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
MX2012001838A (es) 2009-08-12 2012-02-29 Novartis Ag Compuestos de hidrazona heterociclico y sus usos para tratar cancer e inflamacion.
SG10201404886PA (en) 2009-08-17 2014-10-30 Intellikine Llc Heterocyclic compounds and uses thereof
JP5775871B2 (ja) 2009-08-20 2015-09-09 ノバルティス アーゲー ヘテロ環式オキシム化合物
AU2010288534A1 (en) 2009-08-26 2012-03-15 Novartis Ag Tetra-substituted heteroaryl compounds and their use as MDM2 and/or MDM4 modulators
KR20120093867A (ko) 2009-09-10 2012-08-23 아이알엠 엘엘씨 비시클릭 헤테로아릴의 에테르 유도체
NZ599565A (en) 2009-11-04 2013-05-31 Novartis Ag Heterocyclic sulfonamide derivatives useful as mek inhibitors
JP6220126B2 (ja) 2009-11-23 2017-10-25 セルリアン・ファーマ・インコーポレイテッド 治療的送達のためのシクロデキストリンに基づく重合体
WO2011064211A1 (fr) 2009-11-25 2011-06-03 Novartis Ag Dérivés hétérocycliques d'hétéroaryles bicycliques à 6 cycles benzéniques accolés de benzène contenant de l'oxygène
EP2509964B1 (fr) 2009-12-08 2014-04-30 Novartis AG Dérivés sulfonamides hétérocycliques
CU24130B1 (es) 2009-12-22 2015-09-29 Novartis Ag Isoquinolinonas y quinazolinonas sustituidas
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
WO2011090940A1 (fr) 2010-01-19 2011-07-28 Cerulean Pharma Inc. Polymères à base de cyclodextrine pour administration thérapeutique
US20110237686A1 (en) 2010-03-26 2011-09-29 Cerulean Pharma Inc Formulations and methods of use
US20130090342A1 (en) 2010-06-17 2013-04-11 Novartis Ag Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
CN102947275A (zh) 2010-06-17 2013-02-27 诺瓦提斯公司 哌啶基取代的1,3-二氢-苯并咪唑-2-亚基胺衍生物
UA112517C2 (uk) 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
EP2627648A1 (fr) 2010-09-16 2013-08-21 Novartis AG INHIBITEURS DE LA 17a-HYDROXYLASE/C17,20-LYASE
AU2011346567A1 (en) 2010-12-21 2013-07-25 Novartis Ag Bi-heteroaryl compounds as Vps34 inhibitors
JP2014505088A (ja) 2011-02-10 2014-02-27 ノバルティス アーゲー C−METチロシンキナーゼ阻害剤としての[1,2,4]トリアゾロ[4,3−b]ピリダジン化合物
US9127000B2 (en) 2011-02-23 2015-09-08 Intellikine, LLC. Heterocyclic compounds and uses thereof
JP2014507465A (ja) 2011-03-08 2014-03-27 ノバルティス アーゲー フルオロフェニル二環式ヘテロアリール化合物
JP6002210B2 (ja) 2011-04-28 2016-10-05 ノバルティス アーゲー 17α−ヒドロキシラーゼ/C17,20−リアーゼ阻害剤
EA201391820A1 (ru) 2011-06-09 2014-12-30 Новартис Аг Гетероциклические сульфонамидные производные
EP2721007B1 (fr) 2011-06-20 2015-04-29 Novartis AG Composés de cyclohexyl-isoquinolinone
EP2721008B1 (fr) 2011-06-20 2015-04-29 Novartis AG Dérivés de isoquinolinone substitués par un radical hydroxylé en tant que inhibiteurs de p53 (mdm2 or mdm4)
MX2013015001A (es) 2011-06-27 2014-03-31 Novartis Ag Formas solidas y sales de derivados de tetrahidro-pirido-pirimidin a.
AU2012389562A1 (en) 2011-08-17 2014-07-24 Dennis Brown Compositions and methods to improve the therapeutic benefit of subotimally administered chemical compounds including substituted hexitols such as dibromodulcitol
MX339302B (es) 2011-09-15 2016-05-19 Novartis Ag 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como cinasas de tirosina.
WO2013080141A1 (fr) 2011-11-29 2013-06-06 Novartis Ag Composés pyrazolopyrrolidine
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
WO2013093850A1 (fr) 2011-12-22 2013-06-27 Novartis Ag Dérivés quinoline
CN104011045B (zh) 2011-12-22 2016-08-24 诺华股份有限公司 二氢苯并噁嗪和二氢吡啶并噁嗪衍生物
JP2015503517A (ja) 2011-12-23 2015-02-02 ノバルティス アーゲー Bcl2と結合相手の相互作用を阻害するための化合物
CA2859876A1 (fr) 2011-12-23 2013-06-27 Novartis Ag Composes inhibiteurs de l'interaction entre bcl2 et des partenaires de liaison
KR20140104047A (ko) 2011-12-23 2014-08-27 노파르티스 아게 Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물
MX2014007729A (es) 2011-12-23 2015-01-12 Novartis Ag Compuestos para inhibir la interaccion de bcl2 con los componentes de enlace.
US20130178520A1 (en) 2011-12-23 2013-07-11 Duke University Methods of treatment using arylcyclopropylamine compounds
EP2794589A1 (fr) 2011-12-23 2014-10-29 Novartis AG Composés pour inhiber l'interaction de bcl-2 avec des partenaires de liaison
UY34591A (es) 2012-01-26 2013-09-02 Novartis Ag Compuestos de imidazopirrolidinona
EP3964513A1 (fr) 2012-04-03 2022-03-09 Novartis AG Produits combinés comprenant des inhibiteurs de tyrosine kinase et leur utilisation
US9365576B2 (en) 2012-05-24 2016-06-14 Novartis Ag Pyrrolopyrrolidinone compounds
JP6427097B2 (ja) 2012-06-15 2018-11-21 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. 癌を処置するための組成物および該組成物を製造するための方法
EP2879675B1 (fr) 2012-08-06 2019-11-13 Duke University Composés et procédés pour le ciblage de hsp90
EP2914278B1 (fr) 2012-11-05 2021-06-02 Dana-Farber Cancer Institute, Inc. Xbp1, cd138 et cs1, compositions pharmaceutiques qui comprennent les peptides et procédés d'utilisation de tels peptides et compositions
TW201422625A (zh) 2012-11-26 2014-06-16 Novartis Ag 二氫-吡啶并-□衍生物之固體形式
US9556180B2 (en) 2013-01-22 2017-01-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction
EP2948451B1 (fr) 2013-01-22 2017-07-12 Novartis AG Composés de purinone substitués
PL2958943T3 (pl) 2013-02-20 2020-04-30 The Trustees Of The University Of Pennsylvania Leczenie nowotworu złośliwego za pomocą humanizowanego chimerycznego receptora antygenowego anty-egfrviii
WO2014128612A1 (fr) 2013-02-20 2014-08-28 Novartis Ag Dérivés de quinazolin-4-one
HK1219421A1 (zh) 2013-03-15 2017-04-07 因特利凯有限责任公司 激酶抑制剂的组合及其用途
WO2014155268A2 (fr) 2013-03-25 2014-10-02 Novartis Ag Inhibiteurs de kinase tyrosine fgf-r et leur utilisation dans le traitement de maladies associées à un manque ou à une absence d'activité snf5
US20150018376A1 (en) 2013-05-17 2015-01-15 Novartis Ag Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
UY35675A (es) 2013-07-24 2015-02-27 Novartis Ag Derivados sustituidos de quinazolin-4-ona
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
WO2015022663A1 (fr) 2013-08-14 2015-02-19 Novartis Ag Composés et compositions utiles comme inhibiteurs de mek
WO2015022664A1 (fr) 2013-08-14 2015-02-19 Novartis Ag Composés et compositions utiles comme inhibiteurs de mek
AU2014321419B2 (en) 2013-09-22 2017-06-15 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use
WO2015084804A1 (fr) 2013-12-03 2015-06-11 Novartis Ag Combinaison d'un inhibiteur de mdm2 et d'un inhibiteur de braf, et leur utilisation
US10000469B2 (en) 2014-03-25 2018-06-19 Duke University Heat shock protein 70 (hsp-70) receptor ligands
WO2015145388A2 (fr) 2014-03-27 2015-10-01 Novartis Ag Procédés de traitement de cancers colorectaux avec mutations en amont de la voie wnt
CA2943979A1 (fr) 2014-03-28 2015-10-01 Calitor Sciences, Llc Composes heteroaryle substitues et leurs methodes d'utilisation
WO2015153345A1 (fr) 2014-04-03 2015-10-08 Invictus Oncology Pvt. Ltd. Agents thérapeutiques combinatoires supramoléculaires
WO2016011658A1 (fr) 2014-07-25 2016-01-28 Novartis Ag Polythérapie
JP6526789B2 (ja) 2014-07-31 2019-06-05 ノバルティス アーゲー 組み合わせ療法
JP2018527362A (ja) 2015-09-11 2018-09-20 サンシャイン・レイク・ファーマ・カンパニー・リミテッドSunshine Lake Pharma Co.,Ltd. 置換されたヘテロアリール化合物および使用方法
US11261187B2 (en) 2016-04-22 2022-03-01 Duke University Compounds and methods for targeting HSP90
WO2018039203A1 (fr) 2016-08-23 2018-03-01 Oncopep, Inc. Vaccins peptidiques et durvalumab pour le traitement du myélome multiple
CA3034666A1 (fr) 2016-08-23 2018-03-01 Oncopep, Inc. Vaccins peptidiques et durvalumab pour le traitement du cancer du sein
CA3035080A1 (fr) 2016-09-27 2018-04-05 Cero Therapeutics, Inc. Molecules de recepteurs d'engloutissement chimeriques
US10207998B2 (en) 2016-09-29 2019-02-19 Duke University Substituted benzimidazole and substituted benzothiazole inhibitors of transforming growth factor-β kinase and methods of use thereof
US10927083B2 (en) 2016-09-29 2021-02-23 Duke University Substituted benzimidazoles as inhibitors of transforming growth factor-β kinase
WO2019067328A1 (fr) 2017-09-26 2019-04-04 Cero Therapeutics, Inc. Molécules de récepteur d'engloutissement chimérique et méthodes d'utilisation
WO2019083960A1 (fr) 2017-10-24 2019-05-02 Oncopep, Inc. Vaccins peptidiques et inhibiteurs d'hdac pour le traitement du myélome multiple
US12059463B2 (en) 2017-10-24 2024-08-13 Oncopep, Inc. Peptide vaccines and pembrolizumab for treating breast cancer
EP3710006A4 (fr) 2017-11-19 2021-09-01 Sunshine Lake Pharma Co., Ltd. Composés hétéroaryle substitués et leurs méthodes d'utilisation
WO2019119486A1 (fr) 2017-12-21 2019-06-27 中国科学院合肥物质科学研究院 Classe d'inhibiteurs de kinase dérivés de pyrimidine
KR102737185B1 (ko) 2018-01-20 2024-12-05 선샤인 레이크 파르마 컴퍼니 리미티드 치환된 아미노피리미딘 화합물 및 이의 사용 방법
CN112218886A (zh) 2018-03-28 2021-01-12 森罗治疗公司 嵌合吞噬受体的表达载体、基因修饰的宿主细胞及其用途
AU2019243154A1 (en) 2018-03-28 2020-10-01 Cero Therapeutics, Inc. Cellular immunotherapy compositions and uses thereof
EP3774906A1 (fr) 2018-03-28 2021-02-17 Cero Therapeutics, Inc. Récepteurs tim4 chimériques et leurs utilisations
US12220423B2 (en) 2018-07-24 2025-02-11 Hygia Pharmaceuticals, Llc Compounds, derivatives, and analogs for cancer
US20240058446A1 (en) 2019-10-03 2024-02-22 Cero Therapeutics, Inc. Chimeric tim4 receptors and uses thereof
WO2021097256A1 (fr) 2019-11-14 2021-05-20 Cohbar, Inc. Peptides antagonistes de cxcr4
WO2021185844A1 (fr) 2020-03-16 2021-09-23 Pvac Medical Technologies Ltd Utilisation d'une substance et composition pharmaceutique correspondante et traitements médicaux ou utilisations correspondants
WO2021233534A1 (fr) 2020-05-20 2021-11-25 Pvac Medical Technologies Ltd Utilisation d'une substance et composition pharmaceutique associée, et traitements médicaux ou utilisations associées
CN115768890A (zh) 2020-04-15 2023-03-07 加州理工学院 通过分子和物理启动对t细胞免疫疗法的热控制
US20230285576A1 (en) 2020-08-05 2023-09-14 Ellipses Pharma Ltd Treatment of cancer using a cyclodextrin-containing polymer-topoisomerase inhibitor conjugate and a parp inhibitor
WO2022036265A1 (fr) 2020-08-14 2022-02-17 Cero Therapeutics, Inc. Récepteurs chimériques tim et leurs utilisations
WO2022036285A1 (fr) 2020-08-14 2022-02-17 Cero Therapeutics, Inc. Compositions et méthodes de traitement du cancer à l'aide de récepteurs tim chimériques en association avec des inhibiteurs de la poly(adp-ribose)polymérase
WO2022036287A1 (fr) 2020-08-14 2022-02-17 Cero Therapeutics, Inc. Récepteurs chimériques anti-cd72 et utilisations de ceux-ci
WO2022047259A1 (fr) 2020-08-28 2022-03-03 California Institute Of Technology Circuits de signalisation de mammifère synthétiques pour la régulation de population cellulaire robuste
TW202237638A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 烏苷酸環化酶c(gcc)抗原結合劑之組成物及其使用方法
CN117203223A (zh) 2021-02-26 2023-12-08 凯洛尼亚疗法有限公司 淋巴细胞靶向慢病毒载体
US20250127896A1 (en) 2021-07-28 2025-04-24 Cero Therapeutics Holdings, Inc. Chimeric tim4 receptors and uses thereof
US20230391809A1 (en) * 2022-06-07 2023-12-07 Biomimetix Jv, Llc Hydrophobic compositions including a hydrophilic active ingredient and methods relating thereto
CN119816589A (zh) 2022-08-02 2025-04-11 国立大学法人北海道大学 使用细胞器复合体改善细胞疗法的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457105A (en) * 1992-01-20 1995-10-10 Zeneca Limited Quinazoline derivatives useful for treatment of neoplastic disease
WO1996009294A1 (fr) * 1994-09-19 1996-03-28 The Wellcome Foundation Limited Composes heteroaromatiques substitues et leur utilisation en medecine
WO1996027797A2 (fr) * 1995-03-08 1996-09-12 Hsc Research And Development Limited Partnership Inhibiteurs de zap 70 et procedes de traitement de troubles de la transduction de signaux de zap 70

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457105A (en) * 1992-01-20 1995-10-10 Zeneca Limited Quinazoline derivatives useful for treatment of neoplastic disease
WO1996009294A1 (fr) * 1994-09-19 1996-03-28 The Wellcome Foundation Limited Composes heteroaromatiques substitues et leur utilisation en medecine
WO1996027797A2 (fr) * 1995-03-08 1996-09-12 Hsc Research And Development Limited Partnership Inhibiteurs de zap 70 et procedes de traitement de troubles de la transduction de signaux de zap 70

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
A. LEVITZKI: "Receptor activation by antigens, cytokines, hormones and growth factors", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, vol. 766, 1995, pages 363 - 8, XP002053500 *
A. LEVITZKI: "Signal-transduction therapy", EUR. J. BIOCHEM., vol. 226, no. 1, 1994, pages 1 - 13, XP002053501 *
BEN-BASSAT ET AL: "Inhibitors of epidermal growth factor receptor kinase and cyclin dependent kinase 2 activation induce growth arrest, differentiation, and apoptosis of human papilloma virus 16-immortalized human keratinocytes", CANCER RESEARCH, vol. 57, September 1997 (1997-09-01), pages 3741 - 50, XP002053502 *
BRIDGES ET AL: "Tyrosine kinase inhibitors. 8. An unusually step structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD153035), a potent inhibitor of the epidermal growth factor receptor", J MED CHEM, vol. 39, 1996, pages 267 - 76, XP002064936 *
TRAXLER ET AL: "4-Phenyl-amino(pyrrolopyrimidines): potent and selectzive,ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase", J. MED. CHEM., vol. 39, no. 12, December 1996 (1996-12-01), pages 2285 - 92, XP002053503 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE42353E1 (en) 1996-09-25 2011-05-10 Astrazeneca Uk Limited Quinazoline derivatives and pharmaceutical compositions containing them
US7173038B1 (en) 1999-11-05 2007-02-06 Astrazeneca Ab Quinazoline derivatives as VEGF inhibitors
US9040548B2 (en) 1999-11-05 2015-05-26 Astrazeneca Ab Quinazoline derivatives as VEGF inhibitors
US7160889B2 (en) 2000-04-07 2007-01-09 Astrazeneca Ab Quinazoline compounds

Also Published As

Publication number Publication date
CA2265630A1 (fr) 1998-03-19
AU4342997A (en) 1998-04-02
EP0954315A2 (fr) 1999-11-10
WO1998010767A2 (fr) 1998-03-19

Similar Documents

Publication Publication Date Title
WO1998010767A3 (fr) Utilisation de derives de la quinazoline pour la fabrication d'un medicament destine au traitement de troubles cutanes hyperproliferatifs
HUP9901807A3 (en) Heterocycle substituted n-acyl benzenesulfonamide derivatives, process for their preparation and their use as prodrug for the preparation of pharmaceutical compositions treating inflammation or inflammation-associated disorders
AU6974996A (en) Compositions for the treatment of dermatological disorders and methods for their use
HUP0000558A3 (en) Use of active d vitamin analogues for producing pharmaceutical composition for the treatment of prostatic diseases
IL127943A (en) Pharmaceutical and cosmetic compositions for the treatment of skin disorders
AU3990797A (en) Sustained release formulation
EP1806135A3 (fr) Utilisation d'un inhibiteur de la protéine tyrosine tel qu'une génistéine pour le traitement d'une rétinopathie diabétique ou une inflammation oculaire
WO2001028491A3 (fr) Procede et composition utilises afin de traiter les affections dermatologiques
NZ504076A (en) A topical formulation which induces a minimal systemic effect when applied to the skin, the topical formulation comprising an immunosuppressive macrolide selected from sirolimus, FK506 and SDZ ASM 981 and a permeation modulator for the treatment of a dermatological condition
WO2001051051A3 (fr) Agents de traitement des troubles cutanes
PL370795A1 (en) Composition based on etyllinoleate and triethylcitrate for the treatment of seborrhea and acne
CA2392620A1 (fr) Melatonine servant a traiter l'alopecie androgenetique et diffuse
AU2001286562A1 (en) Use of agaricus blazei murill to prevent or treat skin and other disorders
CA2373794A1 (fr) Compositions et utilisation d'et743 pour le traitement du cancer
CA2245766A1 (fr) Compositions pour phototherapie des troubles cutanes proliferants
HUP9904317A3 (en) Use of 1-hydroxy-2-pyridones for producing pharmaceutical compositions suitable for the treatment of skin diseases
AU5774699A (en) Human stearoyl-coa desaturase-related compositions and methods for treating skin disorders
CA2282682A1 (fr) Traitement du psoriasis par le tazarotene et des corticoides
HRP20010133B1 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases
AU7106300A (en) Treatment of skin disorders
HUP0000785A3 (en) Ointment for the treatment of burns and other skin diseases
IE870577L (en) Topical amide preparation
AU2509801A (en) Method for the cosmetic treatment of human skin
WO2000037037A3 (fr) Composition pour le traitement des brulures
NZ302670A (en) Use of 2,3-dihydro-imidazo[2,1-b]benzothiazole derivatives to treat degenerative disorders and ageing of the nervous and vascular systems

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
COP Corrected version of pamphlet

Free format text: PAGES 1-94, DESCRIPTION, REPLACED BY NEW PAGES 1-82; PAGES 95-111, CLAIMS, REPLACED BY NEW PAGES 83-97; PAGES 1/6-6/6, DRAWINGS, REPLACED BY NEW PAGES 1/6-6/6; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT

ENP Entry into the national phase

Ref document number: 2265630

Country of ref document: CA

Ref country code: CA

Ref document number: 2265630

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1997941542

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998513877

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1997941542

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997941542

Country of ref document: EP